In a land of multi-modality imaging giants, OEC has more than held its own with a highly focused niche strategy. Advances in minimally-invasive surgery should further boost OEC, which offers surgeons a different kind of visualization solution. Now OEC has to convince investors of the value of steady, if unspectacular, growth.
by David Cassak
Balzac once remarked that the small are hard to crush because they fit so neatly beneath the feet. Indeed, in...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
